Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 ...

Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets ...
Seeking Alpha

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Recursion Announces Board Transition

Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June ...
Seeking Alpha

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...
Nasdaq

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Insider Monkey

Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best mid cap stocks to buy according to hedge funds. On November 1, TD Cowen analyst Brendan Smith touted the progress the company has made ...
AOL

This $4 Stock Could Be Your Ticket to Millionaire Status

What's the best next use of artificial intelligence (AI)? Plenty of people would say drug development. And they'd arguably be right. That's not something for down the road, though, when AI is more ...
Benzinga.com

Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. RXRX is hovering near ...
The Motley Fool

Why Recursion Pharamaceuticals Topped the Market Today

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. Before market open, ...
Nasdaq

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...